The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 4
  • 1
    Mr. Anurag Bagaria
    Born in November 1976
    Individual (1 offspring)
    Person with significant control
    2022-08-01 ~ now
    PE - Right to appoint or remove directorsCIF 0
  • 2
    Smit, Willem Anton
    Director born in May 1975
    Individual (27 offsprings)
    Officer
    2022-08-01 ~ now
    OF - Director → CIF 0
  • 3
    Mr. Karan Bagaria
    Born in July 1984
    Individual (1 offspring)
    Person with significant control
    2022-08-01 ~ now
    PE - Right to appoint or remove directorsCIF 0
  • 4
    3rd Floor, 5 Lloyds Avenue, London, United Kingdom
    Active Corporate (4 parents, 145 offsprings)
    Equity (Company account)
    2 GBP2021-12-31
    Officer
    2022-08-01 ~ now
    OF - Secretary → CIF 0
parent relation
Company in focus

KEMWELL BIOPHARMA UK LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
02023-04-01 ~ 2024-03-31
02022-08-01 ~ 2023-03-31
Par Value of Share
Class 1 ordinary share
12023-04-01 ~ 2024-03-31
Class 2 ordinary share
12023-04-01 ~ 2024-03-31
Nominal value of shares issued in a specific share issue
Class 2 ordinary share
1 USD2023-04-01 ~ 2024-03-31
Fixed Assets - Investments
6,552,559 USD2024-03-31
1,600,000 USD2023-03-31
Debtors
27,090 USD2024-03-31
Cash at bank and in hand
235,567 USD2024-03-31
2,084,984 USD2023-03-31
Current Assets
262,657 USD2024-03-31
2,084,984 USD2023-03-31
Creditors
Current
11,391 USD2024-03-31
84,283 USD2023-03-31
Net Current Assets/Liabilities
251,266 USD2024-03-31
2,000,701 USD2023-03-31
Total Assets Less Current Liabilities
6,803,825 USD2024-03-31
3,600,701 USD2023-03-31
Equity
Called up share capital
6,947,882 USD2024-03-31
3,686,317 USD2023-03-31
Retained earnings (accumulated losses)
-144,057 USD2024-03-31
-85,616 USD2023-03-31
Equity
6,803,825 USD2024-03-31
3,600,701 USD2023-03-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
10,000 shares2024-03-31
Class 2 ordinary share
3,675,000 shares2024-03-31

  • KEMWELL BIOPHARMA UK LTD
    Info
    Registered number 14267657
    3rd Floor, 5 Lloyds Avenue, London EC3N 3AE
    Private Limited Company incorporated on 2022-08-01 (2 years 11 months). The company status is Active.
    The last date of confirmation statement was made at 2025-02-07
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.